[Treatment of hypertension with a combination of pyridopyridazine derivative with a beta-receptor blocker. Studies on the hemodynamic course (author's transl)].
22 pateints with a fixed, sometimes therapy-resistant (N = 18) hypertension were treated with a new antihypertensive agent, the pyridopyridazine derivative BQ 22-708 and hemodynamically investigated. 14 hypertensives received single oral doses of between 5 and 15 mg, 8 other patients also received additional treatment with a beta-receptor blocker (0.8 mg pindolol i.v.) or calcium antagonist (10 mg verapamil i.v.). In hypertension which is only poorly controllable or resistant, therapy with BQ 22-708 combined with beta-receptor offers a genuine alternative medication.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D002302:Cardiac Output / Q000187:drug effects; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010869:Pindolol / Q000627:therapeutic use; D011724:Pyridazines / Q000627:therapeutic use*; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D011724:Pyridazines; D010869:Pindolol; D014700:Verapamil
Hochdruck-behandlung durch Kombination eines Pyridopyridazin-Derivats mit einem Betarezeptorenblocker. Hämodynamische Verlaufsuntersuchungen.